The tablet formulation of zanubrutinib (Brukinsa; BeOne) is now approved for all five indications throughout quite a few hematological cancers.Nala's MLD was recognized too late for her being handled. She's already unable to stroll or talk, and must be tube-fed.These information spotlight that prognosis is usually delayed, often requiring session w